To maximize the clinical benefits of these distinct classes of therapeutics, several studies have explored concurrent and sequential combinations of MAPK inhibitors and immune checkpoint inhibitors in patients with advanced melanoma; many have examined combinations of BRAF and MEK inhibitors with anti-PD-1 or anti-PD-L1 antibodies in patients with BRAFV600 mutant melanoma. Here, CD274 is linked to melanoma.